Evidence map›Paper›PMID 41460270›Full record

ArticleThe European journal of health economics : HEPAC : health economics in prevention and care2026

Broadening sources of finance for health promotion and disease prevention: Smart capacitating investment.

Maureen Rutten-van Mölken, Holly Whiteley, Balázs Babarczy, Jacob Davies, Lucas Goossens, Lina Papartyte, Alison Maassen, Balázs Nagy, Stephen Wright, Rhiannon Tudor-Edwards and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The European journal of health economics : HEPAC : health economics in prevention and care, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Maureen Rutten-van MölkenErasmus School of Health Policy and Management, Erasmus University Rotterdam, Rotterdam, Netherlands. m.rutten@eshpm.eur.nl.ORCID http://orcid.org/0000-0001-8706-3159
Holly WhiteleyCentre for Health Economics and Medicines Evaluation (CHEME), Bangor University, Bangor, UK.ORCID http://orcid.org/0000-0003-3144-6913
Balázs BabarczyCenter for Health Technology Assessment of Semmelweis University, Budapest, Hungary.ORCID http://orcid.org/0000-0002-8853-8547
Jacob DaviesCentre for Health Economics and Medicines Evaluation (CHEME), Bangor University, Bangor, UK.ORCID http://orcid.org/0009-0009-2734-3568
Lucas GoossensErasmus School of Health Policy and Management, Erasmus University Rotterdam, Rotterdam, Netherlands.ORCID http://orcid.org/0000-0003-4450-4887
Lina PapartyteEuroHealthNet, Brussels, Belgium.
Alison MaassenEuroHealthNet, Brussels, Belgium.ORCID http://orcid.org/0000-0002-5995-3987
Balázs NagyCenter for Health Technology Assessment of Semmelweis University, Budapest, Hungary.ORCID http://orcid.org/0000-0003-4125-7905
Stephen WrightStichting Health ClusterNET, Amsterdam, Netherlands.ORCID http://orcid.org/0000-0002-9747-5349
Rhiannon Tudor-EdwardsCentre for Health Economics and Medicines Evaluation (CHEME), Bangor University, Bangor, UK.ORCID http://orcid.org/0000-0003-4748-5730
Invest4Health Consortium

Funding

HORIZON EUROPE Framework Programme Grant agreement ID: 101095522
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

FinancingHealth promotionHealth technology assessmentInvestmentPreventionPublic–private partnershipSocial impact bond

Identifiers

PMID41460270
PMCPMC13451443

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.